Chai Discovery, a San Francisco-based artificial intelligence drug discovery firm, has raised $400 million in a Series C financing round, according to The Pharma Letter. The deal values the US company at $3.8 billion.
According to The Next Web, the round triples Chai Discovery's valuation and stands as a fresh sign that AI drug discovery has moved "from promise to deployment" at big pharma.
The Pharma Letter reports that the company plans to use the new capital to expand the use of its molecular design technology. Chai Discovery is part of a growing wave of firms applying AI not just to analyze existing compounds, but to help design new ones.
The scale of the raise, and the size of the valuation attached to it, points to rising investor confidence that AI-designed drug discovery is beginning to yield practical tools rather than remaining a research curiosity.
The available reporting does not detail which investors led the round, the specific drugs or targets Chai Discovery is pursuing, or a timeline for bringing any AI-designed candidates to market.
Why it matters: A $400 million bet at a $3.8 billion valuation signals that money is now flowing into AI drug discovery on the expectation it can shorten and cheapen one of the slowest, most expensive processes in medicine.